iPS Cells & Regenerative Medicine– category –
-
FDA Regenerative Medicine Advanced Therapy (RMAT) Designations Hit Record High of 48 in 2025, Accounting for 48% of All Designations in Past Two Years
PharmaLive USA Overview According to a GlobalData report, the number of Regenerative Medicine Advanced Therapy (RMAT) designations granted by the FDA reached a record-breaking 48 in 2025, with designations in 2024 and 2025 collectively a... -
ISSCR to Host iPSC 20th Anniversary Symposium in Kyoto, Japan in October 2026, Celebrating Two Decades of Breakthrough Science
International Society for Stem Cell Research (ISSCR) Japan Overview The International Society for Stem Cell Research (ISSCR) announced a symposium in Kyoto, Japan, in October 2026, commemorating the 20th anniversary of iPSC discovery. Th... -
U.S. FDA RMAT Designations Surge to 165 Total, with Rocket Pharmaceuticals (5) and CRISPR Therapeutics (4) Leading the Way
BioInformant USA Overview As of July 15, 2026, the cumulative number of Regenerative Medicine Advanced Therapy (RMAT) designations publicly announced by the U.S. FDA has reached 165. Rocket Pharmaceuticals and CRISPR Therapeutics are not... -
REPROCELL Unveils StemEdit Hypoimmune iPSCs with HLA Knockout, Accelerating Development of Off-the-Shelf Cell Therapies
REPROCELL (Blog) Japan Overview REPROCELL has announced the launch of its StemEdit hypoimmune iPSC lines, featuring HLA knockout through high-efficiency genome editing and regulatory-compliant cell lines. This technology aims to mitigate... -
Fate Therapeutics Secures FDA IND Clearance for FT839, a Dual iPSC-Derived CAR T-Cell Candidate, with Phase 1/2a Trial Targeting Autoimmune Diseases and Hematologic Malignancies to Commence in H2 2026
GlobeNewswire USA Overview Fate Therapeutics announced FDA IND clearance for FT839, its iPSC-derived dual CAR T-cell product candidate. FT839 is designed to simultaneously target CD19 and CD38, aiming for comprehensive treatment across a... -
Fate Therapeutics’ Off-the-Shelf iPSC-Derived CAR T-Cell Therapy FT819 Shows Promising Early Clinical Data in Treatment-Resistant Systemic Sclerosis
EurekAlert! USA Overview New preliminary clinical data for Fate Therapeutics' off-the-shelf iPSC-derived CAR T-cell therapy, FT819, was presented at ISSCR 2026, targeting patients with treatment-resistant systemic sclerosis. As part of a... -
Phase 1/2a Trial of Autologous iPSC-Derived Dopaminergic Progenitors for Parkinson’s Shows Positive 12-Month Interim Results in 8 Patients, Demonstrating Favorable Safety and Functional Improvement
International Society for Stem Cell Research USA Overview Interim clinical results from the first Phase 1/2a trial of autologous iPSC-derived dopaminergic progenitor cells for Parkinson's Disease were presented at ISSCR 2026, showing fav... -
Landmark Phase 1b/2a REGEN4HD Trial for Huntington’s Disease with Pluripotent Stem Cell-Derived Neural Stem Cells Unveiled at ISSCR 2026
International Society for Stem Cell Research International Overview The first clinical trial (Phase 1b/2a REGEN4HD study) of pluripotent stem cell-derived neural stem cells for Huntington's Disease was highlighted at the ISSCR 2026 annua... -
iPS Cells & Regenerative Medicine Weekly Report July 12, 2026
📄 Weekly Report July 12, 2026 (PDF) — Download Weekly Report July 12, 2026 (PDF) — DownloadDownload 🎙 Podcast July 12, 2026 (MP3) — Play & Download iPS_RegenerativeMedicineEnglishPodcast_20260712.mp3Download View Past Weekly Reports→ -
Vector BioMed Proposes Platform to Accelerate CAR-T Therapy Development from Gene Sequence to Clinic-Ready in Under 12 Months
Vector BioMed USA Overview Vector BioMed is advocating for a platform capable of accelerating CAR-T therapy development from gene sequencing to clinic-ready in under 12 months. This platform aims to reduce therapy costs by adopting a tra...
